Welcome to the Highlights from AAD 2016
We are delighted to bring these highlights from the 74th Annual Meeting of the American Academy of Dermatology (AAD), held in Washington, DC, from March 4 to March 8, 2016.
A very successful International Day preceded the Annual Meeting, and now will be held every year before the meeting. The importance of the international collaboration and contribution to the American Academy of Dermatology is underscored by Dr. Mark Lebwohl, immediate past president of the AAD, in his video remarks elsewhere in this section.
The comprehensive scope of the AAD meeting, from medical dermatology to cosmetic dermatology, is reflected in the highlights. Results from late-breaking research with novel investigational drugs in psoriasis and atopic dermatitis and novel approaches to treating alopecia and rosacea. Updates on treatment and research related to melanoma, cutaneous cancer, psoriasis, and atopic dermatitis are provided.
From the plenary session, we’ve included a look at how genetic screening and other new technologies are changing the diagnosis and treatment of diseases in dermatology and the possibility of ending the HIV/AIDS epidemic.
Psoriasis and atopic dermatitis are undergoing a much-welcomed revolution with new treatments being investigated and coming to clinical practice. The late-breaking research articles bring you updates on new research results with secukinumab, ustekinumab, and ixekizumab in psoriasis, and with crisaborole and nemolizumab in atopic dermatitis. The hot topic updates in psoriasis and atopic dermatitis round out the current view.
The key point summary slides for each article are downloadable to assist with moving this new information into your clinical practice.
Experts in dermatology shared the clinical pearls they learned from AAD 2016 in our video highlights. We invite you to view these to learn how they could impact your clinical practice.
The American Academy of Dermatology has placed its considerable stature behind proposed legislation to limit the use of tanning beds to persons over 18 years old in the United States and a requirement they sign an acknowledgement of risk. During AAD 2016, further success in moving this legislation forward was announced. We encourage dermatologists to support this effort to protect all from skin cancer, and applaud the AAD for its leadership.
View the video interview with Dr. Abel Torres to hear the focus for his year as president of AAD and a welcome to AAD 2017 in Orlando.
We hope these perspectives and new information will contribute to improving the care of your patients, and we look forward to providing more education next year.